Most Read Articles
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 3 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.
3 days ago
The risk of stroke and subsequent mortality is significantly elevated in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), a recent study has shown.

PSA declines predict better overall survival in mCRPC

27 Jul 2017

A decline in prostate-specific antigen (PSA) levels is a significant predictor of better overall survival (OS) in highly pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a new retrospective study reveals.

A retrospective analysis of 129 mCRPC patients on enzalutamide (mean age at diagnosis 66.3±6.3 years) showed that the PSA response rate (>50 percent decline in PSA levels) at 4 weeks was 48.7 percent (n=58).

Additionally, PSA response rates at 8, 12 and 16 weeks were 50.4 (n=58), 49.1 (n=54) and 51.7 (n=47) percent, respectively.

In univariate analysis, a positive PSA response was significantly associated with improved overall survival at 8 (hazard ratio [HR], 0.62; 95 percent CI, 0.41 to 0.94; p=0.023) and 12 (HR, 0.40; 0.26 to 0.62; p<0.001) weeks.

On the other hand, multivariable analysis showed that improved overall survival as significantly related to a positive PSA response only at week 12 (HR, 0.30; 0.16 to 0.57; p<0.001). Survival at week 8 (HR, 0.62; 0.35 to 1.12; p=0.11) was not significantly associated with PSA response. The median overall survival of the cohort was 7.8 months.

Other prognostic factors of overall survival included PSA (HR, 1.49; 1.23 to 1.79; p<0.001), alkaline phosphatase (HR, 1.93; 1.35 to 2.76; p=0.002) and haemoglobin (HR, 0.69; 0.58 to 0.82; p<0.001) levels upon enzalutamide initiation.

Prior treatment with docetaxel (HR, 5.73; 2.73 to 12.02; p<0.001), cabazitaxel (HR, 2.35; 1.57 to 3.52; p<0.001) and abiraterone (HR, 6.54; 3.63 to 11.78; p<0.001) were all also significantly correlated with overall survival.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 3 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.
3 days ago
The risk of stroke and subsequent mortality is significantly elevated in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), a recent study has shown.